Biotech Startups

Resverlogix is a late-stage clinical biotechnology company developing epigenetic therapeutics for patients with chronic illnesses and high unmet medical need. It also offers value-based health solutions to stakeholders such as payer groups.

1 investor

Nanjing Hicin Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company. The page provides only regulatory licensing and copyright information, with no detail on its products or operations.

1 investor

MedChemExpress (Shanghai Haoyuan Pharmaceutical, stock code 688131) is a CRO and CDMO that provides life-science research reagents and drug development, process optimization, and commercial manufacturing of APIs, intermediates, starting materials, and formulations for the global pharmaceutical and biotech industry. It offers an integrated platform covering small molecules, large molecules, and new molecular types from preclinical stages through commercial production.

1 investor

Sinocelltech is a biopharmaceutical company founded in 2002 that develops biologic drugs, with five products approved in China and nine additional candidates in clinical development. It is publicly listed in China (stock code 688520).

1 investor

Santo Biopharma is a drug development company building next-generation lentiviral vector in vivo gene therapies for rare diseases and cancer, including neurofibromatosis, meningioma, and malignant mesothelioma. It develops a fifth-generation lentiviral vector delivery system and serum-free production platforms to support gene therapy research.

1 investor

NeuExcell Therapeutics is a clinical-stage biopharmaceutical company developing neuro-regenerative therapies for neurodegenerative diseases and nerve injuries, with trials targeting glioma, Alzheimer's disease, and stroke. Its technology converts supportive glial cells into functional neurons for in-situ repair of damaged brain tissue.

1 investor

Kubota Holdings is an ophthalmic healthcare solutions company focused on developing pharmaceuticals and medical devices to help maintain and restore vision for people with eye diseases. The group engages in the research and development of treatments and medical technologies for ocular conditions.

1 investor

Uni-medica develops automated fluorescence staining and analysis systems, nucleic acid detection kits, and high-throughput sequencing products for molecular diagnostic applications including cervical cancer screening, pathogen detection, and genetic disease identification. The company serves hospitals and medical laboratories in China.

1 investor

Jiangsu Aidea Pharmaceutical Group is a Chinese pharmaceutical company that develops, manufactures, and sells innovative drugs, focusing on anti-HIV/AIDS therapeutics and prevention as well as human-derived protein biopharmaceuticals. Founded in 2009 and listed on the Shanghai Stock Exchange STAR Market (688488.SH), it operates an integrated human-protein industry chain in China.

1 investor

A Chinese in-vitro diagnostics company that develops diagnostic instruments and reagents, including chemiluminescence immunoassay analyzers, nucleic acid (PCR) testing systems, and fluorescence immunoassay analyzers for clinical and medical laboratories. The company focuses on in-house R&D of core reagent raw materials, open instrument platforms, and reagent solutions.

1 investor

Westlake Omics develops FAXP spatial proteomics technology, which uses tissue volume expansion to improve the quantity and quality of protein identifications while reducing analysis time. The technology targets applications in precision medicine and disease diagnosis.

1 investor

Guizhou Sanli is a traditional Chinese medicine pharmaceutical company covering cultivation, R&D, production, and marketing, producing TCM in 16 dosage forms such as sprays, granules, capsules, pills, and tablets across GMP production lines. Founded in 1995, it is publicly listed on the Shanghai Stock Exchange and operates about ten subsidiaries.

1 investor

Da An Gene is a Chinese state-owned biomedical company focused on molecular diagnostics, developing and producing clinical diagnostic reagents, instruments, and consumables, with a specialty in fluorescent PCR diagnostic reagents. Listed on the Shenzhen Stock Exchange (SZ002030), it serves clinical and in-vitro diagnostics markets and distributes products across many countries.

1 investor

Doer Bio (Zhejiang Doer Biologics) is a biotechnology company focused on the development of innovative biologic drugs. It is a subsidiary of Huadong Medicine (SZ.000963), with its R&D center located in Hangzhou, China.

1 investor

Megarobo (镁伽科技) develops autonomous agents and multi-agent systems combining AI and robotic automation for smart laboratories and intelligent manufacturing. It serves clients in life sciences, chemicals, food and beverage, agriculture, consumer-grade integrated circuits, and new energy, primarily in China.

1 investor

Shenzhen Changjiu Kanglian Biotechnology, founded in 2020, develops, manufactures, and sells neurosurgical devices and consumables focused on brain science and cerebrospinal fluid microenvironment solutions. The company serves the neurosurgery clinical market and is based in Shenzhen, China.

1 investor

Highlight Pharma (高光制药) is a clinical-stage biopharmaceutical company developing novel drugs for autoimmune and inflammatory diseases of the peripheral and central nervous systems. Its pipeline includes selective dual TYK2/JAK1 inhibitors and NLRP3-targeting candidates for conditions such as chronic spontaneous urticaria, rheumatoid arthritis, and neurodegenerative diseases.

1 investor

Gmax Biopharm develops therapeutic monoclonal antibodies targeting G protein-coupled receptors (GPCRs), using proprietary antibody discovery platforms. The company operates in the biotechnology and drug development sector.

1 investor

0 investors

0 investors

0 investors

1nHealth provides digital patient recruitment for clinical research, combining digital recruitment expertise with clinical research and software engineering. It partners with organizations running clinical trials to help meet enrollment goals.

0 investors

0 investors

XXII Century develops reduced-nicotine and natural tobacco products, including low-nicotine cigarettes and additive-free tobacco blends aimed at adult smokers seeking harm reduction. The company also provides proprietary tobacco technologies to support public health research.

0 investors